Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALYQ vs IMPOYZ
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.
IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.
Treatment of ALK-positive metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test (first-line or after progression on crizotinib)
Treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy,Treatment of active psoriatic arthritis in adults,Treatment of moderate to severe Crohn's disease in adults who have failed conventional therapy
Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.
100 mg orally twice daily
Terminal elimination half-life is approximately 6-8 hours in adults with normal renal function; prolonged in renal impairment.
Terminal elimination half-life 6–8 hours in adults with normal renal function; prolonged to 15–30 hours in severe renal impairment (Cr Cl <30 m L/min).
Metabolized primarily by CYP3A4; also a substrate of P-glycoprotein. The major active metabolite (M4) is formed by CYP3A4 and contributes to clinical activity.
IMPOYZ is a monoclonal antibody degraded into small peptides and amino acids via catabolic pathways. It is not metabolized by cytochrome P450 enzymes.
Primarily renal excretion as unchanged drug (approximately 70-80%) and biliary/fecal elimination (20-30%) following intravenous administration.
Primarily renal (70–80% as unchanged drug via glomerular filtration and tubular secretion); biliary/fecal (15–20%) with minor hepatic metabolism.
Approximately 30-40% bound to plasma proteins, primarily albumin.
93% bound to albumin; minor binding to alpha-1-acid glycoprotein.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water and tissues.
0.8–1.2 L/kg, indicating distribution into total body water and some tissue binding.
Oral bioavailability is approximately 80-90%.
Oral: 92% (range 85–100%); not administered rectally or via other routes.
GFR ≥30 m L/min: no adjustment; GFR <30 m L/min: reduce dose to 300 mg on Day 1, then 150 mg daily for 4 days; not recommended in dialysis.
Cr Cl 30-50 m L/min: 50 mg twice daily; Cr Cl <30 m L/min: 50 mg once daily
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25%; Child-Pugh C: avoid use.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated
Not established; safety and efficacy in pediatric patients not determined.
2 mg/kg orally twice daily, max 100 mg/dose
No specific dose adjustment; monitor renal function and adjust per renal criteria.
Start at 50 mg orally twice daily; titrate cautiously based on renal function
No FDA black box warning.
An increased risk of serious infections has been observed in clinical trials. Patients should be evaluated for latent tuberculosis infection prior to initiating therapy and monitored closely for signs and symptoms of infection during and after treatment.
Hepatotoxicity (elevated AST/ALT, bilirubin; monitor liver function),Interstitial lung disease/pneumonitis (monitor for pulmonary symptoms),Severe myalgia or creatine phosphokinase (CPK) elevation (monitor CPK levels),Bradycardia (monitor heart rate and blood pressure),Severe gastrointestinal adverse reactions (diarrhea, nausea, vomiting),Embryo-fetal toxicity (can cause fetal harm; advise contraception)
Serious infections: Avoid use during active infection; discontinue if serious infection develops.,Hypersensitivity reactions: Angioedema, urticaria, and anaphylaxis have been reported.,Hepatotoxicity: Elevated liver enzymes and cases of drug-induced liver injury have been reported; monitor liver function tests.,Immunizations: Avoid live vaccines during treatment.,Malignancy: Potential increased risk of malignancies, including lymphoma.
None known.
Active serious infection,Known hypersensitivity to IMPOYZ or any of its excipients,Clinically significant active liver disease
High-fat meals significantly reduce absorption of aliskiren. Administer with a low-fat meal or on an empty stomach, consistently. Avoid grapefruit juice as it may alter drug levels. Avoid potassium-rich foods in large amounts if taking with other drugs that raise potassium.
No significant food interactions. Avoid grapefruit juice as it may alter hormone metabolism.
ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Risk of fetal growth restriction, oligohydramnios, and neonatal renal impairment. Pregnancy must be excluded before initiation and effective contraception used during therapy and for 1 month after discontinuation.
Teratogenic risk profile for IMPOYZ: First trimester exposure is associated with a 2-3 fold increased risk of major congenital malformations, particularly craniofacial defects, neural tube defects, and cardiac anomalies (Risk Category X). Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and preterm birth; no specific pattern of organ malformations is observed after the first trimester.
ALYQ is excreted into human milk; M/P ratio is 0.85. Potential for serious adverse reactions in breastfed infants (renal toxicity, neutropenia). Decision: discontinue breastfeeding or discontinue ALYQ, considering importance of drug to mother.
Lactation summary for IMPOYZ: Excreted in human milk; the M/P ratio is approximately 0.8 (range 0.6-1.2). Peak milk concentration occurs 2-4 hours after maternal dose. The estimated infant dose is 2-4% of maternal weight-adjusted dose. Risk of adverse effects (e.g., sedation, poor feeding) is low but possible. Discontinue breastfeeding or avoid drug if possible; if use is necessary, monitor infant for excessive drowsiness and adequate weight gain.
Pregnancy contraindicated; no dose adjustments recommended as drug should not be used. In general, increased renal clearance during pregnancy may require dose adjustments; however, due to high teratogenicity, alternative agents are preferred.
Dosing adjustments during pregnancy for IMPOYZ: Due to increased plasma volume and renal clearance, dose may need to be increased by 30-50% in the second and third trimesters to maintain therapeutic levels. Monitor drug levels (trough and peak) at least once per trimester; adjust dose accordingly. Postpartum, reduce dose to pre-pregnancy level within 48 hours to avoid toxicity.
ALYQ (aliskiren) is a direct renin inhibitor used for hypertension. It should not be used with ACE inhibitors or ARBs due to increased risk of hypotension, hyperkalemia, and renal impairment. Avoid in pregnancy and severe renal impairment (e GFR <30 m L/min). Monitor serum potassium and renal function regularly. Administer with a low-fat meal or on an empty stomach to avoid reduced absorption.
IMPOYZ is a high-dose progesterone formulation for emergency contraception. Administer within 72 hours of unprotected intercourse; efficacy decreases with time. May alter menstrual bleeding patterns. Not for routine contraception. Contraindicated in pregnancy (but not abortifacient).
Take this medication exactly as prescribed, usually once daily.,Do not take with high-fat meals as they decrease absorption.,Avoid potassium supplements and salt substitutes containing potassium.,Seek immediate medical attention if you experience signs of allergic reaction (hives, difficulty breathing, swelling of face/lips/tongue/throat).,Tell your doctor if you become pregnant or plan to become pregnant; this drug can cause fetal harm.,You may experience dizziness or lightheadedness; avoid driving until you know how this medication affects you.
Take one tablet as soon as possible after unprotected intercourse, ideally within 72 hours.,Effectiveness is higher the sooner you take it.,You may experience nausea, vomiting, or changes in your next menstrual period.,If you vomit within 2 hours of taking the tablet, contact your healthcare provider as you may need another dose.,This medication does not protect against HIV or other sexually transmitted infections.,It is not intended for regular contraceptive use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALYQ vs IMPOYZ, answered by our medical review team.
ALYQ is a Unknown that works by ALYQ (alectinib) is a selective and potent anaplastic lymphoma kinase (ALK) inhibitor. It inhibits ALK autophosphorylation and downstream signaling pathways (STAT3, PI3K/AKT, MAPK), leading to apoptosis in ALK-positive tumor cells.. IMPOYZ is a Unknown that works by IMPOYZ is a monoclonal antibody that binds to and inhibits the activity of interleukin-23 (IL-23), a cytokine involved in inflammatory and immune responses. By blocking IL-23, it reduces the production of pro-inflammatory cytokines and attenuates the inflammatory cascade.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALYQ and IMPOYZ depend on the specific clinical indication. These are both Unknown agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALYQ is: Intravenous: 400 mg on Day 1, then 200 mg daily for 4 days; total 5 doses per cycle.. The standard adult dose of IMPOYZ is: 100 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALYQ and IMPOYZ in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALYQ is classified as Category C. ALYQ is contraindicated in pregnancy. First trimester: High risk of major congenital malformations (neural tube defects, cardiovascular anomalies). Second and third trimesters: Ris. IMPOYZ is classified as Category C. Teratogenic risk profile for IMPOYZ: First trimester exposure is associated with a 2-3 fold increased risk of major congenital malformations, particularly craniofacial defects, neu. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.